Snowball logo
logo
ZEG_logo

AstraZeneca PLC

€153.50-€0.10  (0.07%)
Estimate
P/E
26.7
EPS
5.74
Beta
0.212
Growth
Revenue, YoY
9.26%
Net income, YoY
5.06%
FCF, YoY
-116.84%
Dividends
Dividend yield
1.47%
Annual payout
£1.90
Next ex. div date
February 6, 27
Payout
47.05%
Div.growth, 5y
2.53%
Div.rating
About the company
Ticker
ZEG
ISIN
GB0009895292
Country
United Kingdom
Sector (GICS)
Healthcare
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies for rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of oral candidates, with the potential to treat diseases across multiple indications; Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates; and Carterra, Inc. to advances lab-in-the-loop drug discovery through new scientific research collaboration. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in

Frequently asked questions

What sector does AstraZeneca PLC (ZEG) operate in?

AstraZeneca PLC belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.

What is AstraZeneca PLC (ZEG) current stock price?

As of the latest data, AstraZeneca PLC stock price is €153.50, with a previous close of €153.60. AstraZeneca PLC lost -€0.10 in the last trading session, representing a -0.07% loss.

What is AstraZeneca PLC (ZEG) current market capitalization?

AstraZeneca PLC market cap is approximately 238.06 billion.

What is AstraZeneca PLC (ZEG) Earnings Per Share (EPS)?

The trailing EPS is €5.74.

What is AstraZeneca PLC (ZEG) Price-to-Earnings (P/E) ratio?

AstraZeneca PLC current P/E ratio is 26.74.

What is AstraZeneca PLC (ZEG) EBITDA?

AstraZeneca PLC EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 4.52 billion.

Does AstraZeneca PLC (ZEG) pay dividends?

Yes. AstraZeneca PLC pays semiannual dividends with an annualized yield of 1.47% and an estimated annual payout of €1.90 per share.

When is the next ex-dividend date for AstraZeneca PLC (ZEG)?

The next ex-dividend date is scheduled for February 06, 2027.

When is AstraZeneca PLC (ZEG) next earnings report?

AstraZeneca PLC is expected to release its next earnings report on September 30, 2026.

What is AstraZeneca PLC (ZEG) beta (volatility) score?

AstraZeneca PLC has a beta of 0.212, indicating lower volatility than the overall market.